EVOQ Trademark

Trademark Overview


On Wednesday, May 25, 2022, a trademark application was filed for EVOQ with the United States Patent and Trademark Office. The USPTO has given the EVOQ trademark a serial number of 97428106. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Tuesday, October 15, 2024. This trademark is owned by EVOQ Therapeutics. The EVOQ trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

(Based on Intent to Use) Diagnostic preparations for medical purposes for detecting the presence of autoimmune disorders and conditions; pharmaceutical preparations and products for immunotherapy treatments; pharmaceutical preparations and products for the treatments of cancers and autoimmune diseases

(Based on Use in Commerce) Consultancy in the field of the medical treatment of autoimmune diseases and cancers; medical treatment of autoimmune disorders and conditions; medical testing and diagnostic services for treatment purposes in the field of autoimmune disorders and conditions; immunotherapy treatments; immunotherapy treatments for cancers and autoimmune disease; medical diagnostic testing, monitoring, and reporting services

(Based on Use in Commerce) Medical research in the field of autoimmune diseases and cancers; medical research and development in the field of development of immunotherapy treatments
evoq

General Information


Serial Number97428106
Word MarkEVOQ
Filing DateWednesday, May 25, 2022
Status760 - EX PARTE APPEAL PENDING
Status DateTuesday, October 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Services(Based on Intent to Use) Diagnostic preparations for medical purposes for detecting the presence of autoimmune disorders and conditions; pharmaceutical preparations and products for immunotherapy treatments; pharmaceutical preparations and products for the treatments of cancers and autoimmune diseases
Goods and Services(Based on Use in Commerce) Consultancy in the field of the medical treatment of autoimmune diseases and cancers; medical treatment of autoimmune disorders and conditions; medical testing and diagnostic services for treatment purposes in the field of autoimmune disorders and conditions; immunotherapy treatments; immunotherapy treatments for cancers and autoimmune disease; medical diagnostic testing, monitoring, and reporting services
Goods and Services(Based on Use in Commerce) Medical research in the field of autoimmune diseases and cancers; medical research and development in the field of development of immunotherapy treatments

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 1, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 1, 0001
Primary Code042
First Use Anywhere DateSaturday, April 30, 2016
First Use In Commerce DateSaturday, April 30, 2016

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, June 1, 2022
Primary Code044
First Use Anywhere DateSaturday, April 30, 2016
First Use In Commerce DateSaturday, April 30, 2016

Trademark Owner History


Party NameEVOQ Therapeutics
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressAnn Arbor, MI 48109

Trademark Events


Event DateEvent Description
Thursday, January 12, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, May 28, 2022NEW APPLICATION ENTERED
Wednesday, June 1, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 12, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 12, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 13, 2023ASSIGNED TO EXAMINER
Monday, March 27, 2023NON-FINAL ACTION WRITTEN
Monday, March 27, 2023NON-FINAL ACTION E-MAILED
Monday, March 27, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 27, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 30, 2023ASSIGNED TO LIE
Friday, December 1, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 1, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 14, 2024FINAL REFUSAL WRITTEN
Wednesday, February 14, 2024FINAL REFUSAL E-MAILED
Wednesday, February 14, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, May 2, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 2, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 2, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, May 13, 2024EXPARTE APPEAL RECEIVED AT TTAB
Monday, May 13, 2024EX PARTE APPEAL-INSTITUTED
Monday, May 13, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, June 28, 2024ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Friday, June 28, 2024NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Friday, June 28, 2024ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Wednesday, August 14, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Tuesday, October 15, 2024NOTIFICATION OF EXAMINERS STATEMENT E-MAILED
Tuesday, October 15, 2024EXAMINERS STATEMENT - COMPLETED
Tuesday, October 15, 2024EXAMINERS STATEMENT E-MAILED